Views & Analysis | Perspectives on pharma industry issues

R&D

handshake and corporate body in the background of

Changing Faces: Pharma and biotech, March 2026

A broad mix of senior leadership and scientific and commercial appointments shaped last month’s pharma and biotech hiring activity.

Market Access

General Counsel in corporate environment

For life sciences, it’s not only about when to bring on a GC...

For founders, the question is no longer just who to hire as GC, but when to hire them, and what comes next.

Patients

Female patient engages with her female doctor

Return on Engagement (ROE): A new framework to better captur...

Return on Engagement (ROE) is a call to action to better capture the multifaceted value of patient engagement.

Oncology

LSX2026: Addressing adult eye cancer, with Roi Raz

Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.

Market Access

Young girl gives high five to her female doctor, mum also in the consult room

A step forward, but not the finish line: What NICE’s QALY up...

Healthcare in the UK is at an inflection point.

Sales & Marketing

Neil Newhouse, Kathy Rice, Greg Walden, and Friz Bittenbender at BIO 2024

At BIO 2024, an industry vows to reclaim its narrative

At BIO2024 experts agreed that in a period where pharma is deeply unpopular, the industry must be proactive in telling its story.

Digital

The art of software

Harnessing the power of technology seems to be on the agenda for many life sciences companies these days.

R&D

BIO 2024 - Live Coverage Day Two

Tune in for updates from BIO 2024 in San Diego on Wednesday, June 5th.

Sales & Marketing

How war in the Middle East is disrupting medical supply chai...

The impact of the geopolitical disruption is starting to tell on global supply chains for medicines and key chemicals for the pharmaceutical industry.

Sales & Marketing

Interview with Craig Ackerman Reuters at Pharma USA 2026

Biotech is back, with Craig Ackerman

In Philadelphia last month, pharmaphorum spoke with Craig Ackerman, a partner at the Alexander Group, about launches, AI best practices, and more.

Digital

Augmented intelligence: The next-gen engine for biopharma in...

Augmented intelligence is strategically valuable because it strengthens both the scientific and financial case for every decision.

Digital

lady pointing at a number of data points

Solution Spotlight: Medscape AI

Medscape AI introduces a global, medical-grade AI search tool exclusively curated from the world’s largest body of clinically vetted content.

Market Access

For life sciences, it’s not only about when to bring on a GC...

For founders, the question is no longer just who to hire as GC, but when to hire them, and what comes next.

Market Access

A step forward, but not the finish line: What NICE’s QALY up...

Healthcare in the UK is at an inflection point.

Oncology

LSX2026: Addressing adult eye cancer, with Roi Raz

Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.

Oncology

From preclinical toxicology to clinical safety: The path for...

Successfully navigating the process for drugs with a higher risk-benefit ratio requires a tailored non-clinical programme design.

Oncology

Advancing the case for cell and gene therapies

After the Advanced Therapies Congress, Europe, pharmaphorum spoke with Resolution Therapeutics' Lara Campana and Vianautis' Dr Sam Barker.

Patients

Return on Engagement (ROE): A new framework to better captur...

Return on Engagement (ROE) is a call to action to better capture the multifaceted value of patient engagement.

Patients

Brain puzzle with piece missing, letting through the sunlight

Exploring mixed episodes in bipolar I disorder: When mania a...

One of the most misunderstood and often overlooked aspects of BD-I is the occurrence of mixed episodes.

Patients

Interview with Matt Wadyka at Reuters Pharma USA 2026

Making direct-to-patient work, with Matt Wadyka

Matt Wadyka, chief client strategy officer at Inizio Medical, spoke to pharmaphorum about the ins and outs of direct-to-patient programmes in pharma.

Changing Faces: Pharma and biotech, March 2026

For life sciences, it’s not only about when to bring on a GC...

Return on Engagement (ROE): A new framework to better captur...

LSX2026: Addressing adult eye cancer, with Roi Raz

A step forward, but not the finish line: What NICE’s QALY up...

At BIO 2024, an industry vows to reclaim its narrative

The art of software

BIO 2024 - Live Coverage Day Two

How war in the Middle East is disrupting medical supply chai...

Biotech is back, with Craig Ackerman

Augmented intelligence: The next-gen engine for biopharma in...

Solution Spotlight: Medscape AI

For life sciences, it’s not only about when to bring on a GC...

A step forward, but not the finish line: What NICE’s QALY up...

LSX2026: Addressing adult eye cancer, with Roi Raz

From preclinical toxicology to clinical safety: The path for...

Advancing the case for cell and gene therapies

Return on Engagement (ROE): A new framework to better captur...

Exploring mixed episodes in bipolar I disorder: When mania a...

Making direct-to-patient work, with Matt Wadyka

Changing Faces: Pharma and biotech, March 2026

A data-driven guide to small molecule drug discovery and dev...

Looking to gene therapy for ocular diseases, with Lance Bald...

Senju launches first-in-class dry eye disease drug in Japan

Using AI-driven synthetic personas to take your insights fur...

Sales & Marketing

Digital

Market Access

Editor's Picks

Oncology

Patients

R&D

Editor's Picks